Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers
Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers
复制标题
DOI：
10.1007/978-1-4939-9706-0_2
复制
发表时间：
2019-01-01
期刊：
影响因子：
--
通讯作者：
Del Campo, Marta
中科院分区：
文献类型：
--
作者：
Hok-A-Hin, Yanaika S.;Willemse, Eline A. J.;Del Campo, Marta
神经系统疾病领域迫切需要生物标志物来进行早期诊断，并在临床试验中对患者进行最佳分层，或监测疾病进展。脑脊液（CSF）是鉴定神经系统疾病新蛋白生物标志物的主要来源之一。尽管在鉴定新的脑脊液生物标志物方面付出了巨大的努力，但在不同研究中观察到的高度可变性阻碍了它们在临床实践中的验证和实施。这种可变性部分是由不同的分析前混淆因素对蛋白质稳定性的影响引起的，这突出了制定和遵守标准化操作程序的重要性。在本章中，我们描述了在过去十年中建立的脑脊液处理和生物库的国际共识分析前指南，特别关注分析前混淆因素对全球脑脊液蛋白质组的影响。此外，我们使用两种新型大型复合蛋白阵列（SOMAscan和Olink）提供了不同延迟储存和冷冻/解冻条件对脑脊液蛋白质组的影响的新结果。遵守共识指南将可能促进脑脊液蛋白生物标志物在研究和临床环境中的成功开发和实施，最终促进疾病修饰疗法的成功开发。
The field of neurological diseases strongly needs biomarkers for early diagnosis and optimal stratification of patients in clinical trials or to monitor disease progression. Cerebrospinal fluid (CSF) is one of the main sources for the identification of novel protein biomarkers for neurological diseases. Despite the enormous efforts employed to identify novel CSF biomarkers, the high variability observed across different studies has hampered their validation and implementation in clinical practice. Such variability is partly caused by the effect of different pre-analytical confounding factors on protein stability, highlighting the importance to develop and comply with standardized operating procedures. In this chapter, we describe the international consensus pre-analytical guidelines for CSF processing and biobanking that have been established during the last decade, with a special focus on the influence of pre-analytical confounders on the global CSF proteome. In addition, we provide novel results on the influence of different delayed storage and freeze/thaw conditions on the CSF proteome using two novel large multiplex protein arrays (SOMAscan and Olink). Compliance to consensus guidelines will likely facilitate the successful development and implementation of CSF protein biomarkers in both research and clinical settings, ultimately facilitating the successful development of disease-modifying therapies.